Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 339.62B |
| Revenue (ttm) | 77.35B |
| Net Income (ttm) | 19.34B |
| Shares Out | n/a |
| EPS (ttm) | 7.97 |
| PE Ratio | 17.56 |
| Forward PE | 15.11 |
| Dividend | 4.62 (3.45%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 32 |
| Average Volume | 3,222 |
| Open | 134.18 |
| Previous Close | 133.36 |
| Day's Range | 133.72 - 134.24 |
| 52-Week Range | 128.16 - 161.30 |
| Beta | n/a |
| RSI | 69.77 |
| Earnings Date | Jul 16, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care,...
Flow of funds moves into Dow and small cap stocks.
The market rotated out of the large-cap tech stocks today. Markets got a little spooked by better than expected JOLT job openings and the realization that July is probably not a month for a rate cut. ...
Johnson & Johnson: Patience Will Be Rewarded
Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, t...
This Changes Everything: One Of The Most Important Shifts For Dividend Investors
Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its ba...
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
Tech stocks rally: Semiconductors lead the charge while healthcare stumbles
Sector Overview Today’s stock market heatmap presents a dynamic landscape, with technology leading the charge. The semiconductor sector shines brightly, spearheaded by Nvidia (NVDA), which is up by 1....
Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years
The Dividend Income Accelerator Portfolio balances income, growth, and capital appreciation, now enhanced by the global diversification from Allianz and LVMH. We focus on financially healthy companies...
Best Dividend Kings: June 2025
Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a c...
Johnson & Johnson reports positive results from Imaavy study
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic a...
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic a...
Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing
Donald Trump Jr . has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)’s approach to healthcare pricing. Despite their political difference...
Johnson & Johnson Unusual Options Activity For June 20
Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson . Looking at options history for Johnson & Johnson (NYSE: JNJ) we detected 9 trades. If we consider the...
If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification
I added Allianz and LVMH to The Dividend Income Accelerator Portfolio for their blend of dividend yield, growth, and financial strength. Both companies offer strong dividend growth potential—Allianz w...
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happe...
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit
BOSTON--(BUSINESS WIRE)--A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ)...
New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Know
An official report on June 17, 2025 reveals Representative Thomas Kean's recent purchase of Amazon.com (NASDAQ: AMZN) stock, valued between $4,004 and $60,000. The transaction took place on May 8, 20...
Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big ph...
Peering Into Johnson & Johnson's Recent Short Interest
Johnson & Johnson's (NYSE: JNJ) short percent of float has fallen 15.79% since its last report. The company recently reported that it has 19.22 million shares sold short , which is 0.8% of all regula...
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...
I'm Buying Dividend Aristocrats At Bargain Basement Prices
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-cove...
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf ap...
Johnson & Johnson CEO: 'We're in the Golden Era of Medical Innovation'
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big ph...